Clinical trial: Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting (NCT04370782)

Eligibility criteria:
Inclusion Criteria:

          -  Able to read and understand informed consent.

          -  High initial clinical suspicion by physician based on signs and symptoms (fever,
             cough, myalgias, fatigue, shortness of breath) followed by RT-PCR for confirmation of
             COVID-19 diagnosis

          -  Any gender

          -  Age 60 years and older

          -  Age 30-59 years with one or more of the following:

               -  abnormal lung exam

               -  abnormal oxygen staturation <95%

               -  abnormal chest x-ray or chest CT

               -  persistent fever >100.4 degrees Fahrenheit upon arrival to Emergency department
                  (ED)

               -  one of the following co-morbidities: hypertension, diabetes mellitus, history of
                  coronary artery disease, chronic kidney disease (CKD), asthma, chronic
                  obstructive pulmonary disease, current or former smoker, or morbid obesity (Body
                  Mass Index ≥35)

        Exclusion Criteria:

          -  Pregnant or breastfeeding female

          -  Severe COVID-19 requiring admission for inpatient treatment

          -  Need for any oxygen supplementation

          -  Need for mechanical ventilatory support

          -  History of oxygen supplementation dependency

          -  History of cancer with ongoing chemotherapy or radiation therapy

          -  Concurrent antimicrobial therapy

          -  Known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds

          -  Already taking hydroxychloroquine or chloroquine within 1 month

          -  Known G6-PD deficiency

          -  History of retinopathy

          -  History of current cardiac diseases (heart failure, ventricular arrhythmias, Left
             bundle branch block and/or Right bundle branch block, QTc prolongation >480ms), or
             family history of sudden cardiac death

          -  Ongoing use of drugs that prolong the QTc interval (antipsychotics, antidepressants,
             class I and III antiarrhythmics, triptans)

          -  Severe renal disease: glomerular filtration rate (GFR) <30ml/min

          -  Severe hepatic impairment (elevated total bilirubin >2 mg/dL, decreased albumin <2.8
             g/dL, signs of jaundice and ascites.)

          -  Active alcohol abuse (>5 drinks per day or >20 drinks per week.)

          -  Seizure disorder, currently on medications

          -  Known hypersensitivity to any tetracyclines.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 30 Years old.


Patient description (medical language): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient description (patient's own words): I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Does the patient match the trial criteria? Contradiction